Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.
作者： Robert Winn , Sechler , Cizmic , Avasarala , Van Scoyk
DOI: 10.2147/PGPM.S26058
关键词: Internal medicine 、 Pharmacology 、 Colorectal cancer 、 Medicine 、 Lung cancer 、 Oncology 、 Treatment of lung cancer 、 Cancer 、 Targeted therapy 、 Breast cancer 、 Drug resistance 、 Personalized medicine
摘要: Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy and in some cases lower toxicity than conventional treatment. Although targeted therapeutics have helped immensely treatment several cancers, like chronic myelogenous leukemia, colon cancer, breast benefit these agents lung remains limited, part due to development drug resistance. In this review, we discuss mechanisms resistance current strategies used treat cancer. A better understanding drug-resistance could potentially from a more robust personalized medicine approach
sci-hub.se 参考文章(130)
Martin Reck, Ulrich Gatzemeier, Thalidomide in lung cancer therapy—what have we learned? Nature Reviews Clinical Oncology. ,vol. 7, pp. 134- 135 ,(2010) , 10.1038/NRCLINONC.2010.11
Andrew J. Weickhardt, Micol S. Rothman, Smita Salian-Mehta, Katja Kiseljak-Vassiliades, Ana B. Oton, Robert C. Doebele, Margaret E. Wierman, D. Ross Camidge, Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. ,vol. 118, pp. 5302- 5309 ,(2012) , 10.1002/CNCR.27450
Yasushi Hoshikawa, Tracy L. Gesell, Alvin M. Malkinson, Robert L. Keith, York E. Miller, Mark W. Geraci, Heiko A. Golpon, Raphael A. Nemenoff, Bifeng Gao, Mark D. Moore, Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer Cancer Research. ,vol. 62, pp. 734- 740 ,(2002)
G Carpenter, S Cohen, Epidermal growth factor. Journal of Biological Chemistry. ,vol. 265, pp. 7709- 7712 ,(1972) , 10.1016/S0021-9258(19)38983-5
Sen Zhang, Frank Wang, Jeffrey Keats, Xiaotian Zhu, Yaoyu Ning, Scott D. Wardwell, Lauren Moran, Qurish K. Mohemmad, Rana Anjum, Yihan Wang, Narayana I. Narasimhan, David Dalgarno, William C. Shakespeare, Juan J. Miret, Tim Clackson, Victor M. Rivera, Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chemical Biology & Drug Design. ,vol. 78, pp. 999- 1005 ,(2011) , 10.1111/J.1747-0285.2011.01239.X
Robert A. Winn, Rubin M. Tuder, "Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy. American Journal of Respiratory and Critical Care Medicine. ,vol. 183, pp. 970- 972 ,(2011) , 10.1164/RCCM.201012-1970ED
M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7506
Meredith A. Tennis, Michelle Van Scoyk, Lynn E. Heasley, Katherine Vandervest, Mary Weiser-Evans, Scott Freeman, Robert L. Keith, Pete Simpson, Raphael A. Nemenoff, Robert A. Winn, Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. ,vol. 12, pp. 244- 253 ,(2010) , 10.1593/NEO.91690
Meredith A. Tennis, Michelle Vanscoyk, Robert L. Keith, Robert A. Winn, The role of prostacyclin in lung cancer Translational Research. ,vol. 155, pp. 57- 61 ,(2010) , 10.1016/J.TRSL.2009.06.010
Joel W. Neal, Lecia V. Sequist, Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh. Current Treatment Options in Oncology. ,vol. 11, pp. 36- 44 ,(2010) , 10.1007/S11864-010-0120-6